Baseline characteristics of participants in the trial (SPRINT or ACCORD-BP) according to the treatment assignment
| Variables . | Intensive treatment group (target SBP <120 mmHg; N = 5334) . | Standard treatment group (target SBP <140 mmHg; N = 5338) . |
|---|---|---|
| Age, mean (SD), year | 65.4 (8.3) | 65.6 (8.5) |
| Female, % | 2191 (41.1) | 2161 (40.5) |
| Race/ethnicity, % | ||
| Non-Hispanic White | 3165 (58.3) | 3102 (58.1) |
| Non-Hispanic Black | 1378 (25.8) | 1469 (27.5) |
| Hispanic | 489 (9.2) | 479 (9.0) |
| Other | 302 (5.7) | 288 (5.4) |
| Education status, % | ||
| Less than college | 3592 (67.3) | 3538 (66.3) |
| College or above | 1742 (32.7) | 1800 (33.7) |
| Uninsured, % | 673 (12.6) | 666 (12.5) |
| Living alone, % | 1317 (24.7) | 1382 (25.9) |
| Smoking, % | 676 (12.7) | 719 (13.5) |
| SBP, mean (SD), mmHg | 139.2 (15.8) | 139.5 (15.5) |
| BMI, mean (SD), kg/m2 | 31.1 (5.4) | 31.0 (5.2) |
| Total cholesterol, mean (SD), mg/dL | 191.8 (43.0) | 190.9 (42.1) |
| HDL cholesterol, mean (SD), mg/dL | 49.7 (14.2) | 49.9 (14.6) |
| eGFR, mL/min/1.73 m2, % | ||
| ≥90 | 1548 (29.0) | 1539 (28.9) |
| 60 to <90 | 2665 (50.0) | 2666 (49.9) |
| 45 to <60 | 768 (14.4) | 796 (14.9) |
| <45 | 353 (6.6) | 337 (6.3) |
| Clinical CVD, % | 1233 (23.1) | 1193 (22.4) |
| Statin use, % | 2781 (52.1) | 2872 (53.8) |
| Antihypertensive use medications, % | ||
| 0 | 534 (10.1) | 559 (10.9) |
| 1 | 1786 (33.5) | 1800 (33.7) |
| ≥2 | 3014 (56.5) | 2959 (55.4) |
| History of diabetesa | 2239 (42.0) | 2244 (42.0) |
| 10-year Framingham CVD risk %, median (IQR) | 22.7 (19.6) | 22.6 (19.4) |
| 10-year ASCVD risk %, median (IQR) | 22.3 (12.8) | 22.5 (13.0) |
| Variables . | Intensive treatment group (target SBP <120 mmHg; N = 5334) . | Standard treatment group (target SBP <140 mmHg; N = 5338) . |
|---|---|---|
| Age, mean (SD), year | 65.4 (8.3) | 65.6 (8.5) |
| Female, % | 2191 (41.1) | 2161 (40.5) |
| Race/ethnicity, % | ||
| Non-Hispanic White | 3165 (58.3) | 3102 (58.1) |
| Non-Hispanic Black | 1378 (25.8) | 1469 (27.5) |
| Hispanic | 489 (9.2) | 479 (9.0) |
| Other | 302 (5.7) | 288 (5.4) |
| Education status, % | ||
| Less than college | 3592 (67.3) | 3538 (66.3) |
| College or above | 1742 (32.7) | 1800 (33.7) |
| Uninsured, % | 673 (12.6) | 666 (12.5) |
| Living alone, % | 1317 (24.7) | 1382 (25.9) |
| Smoking, % | 676 (12.7) | 719 (13.5) |
| SBP, mean (SD), mmHg | 139.2 (15.8) | 139.5 (15.5) |
| BMI, mean (SD), kg/m2 | 31.1 (5.4) | 31.0 (5.2) |
| Total cholesterol, mean (SD), mg/dL | 191.8 (43.0) | 190.9 (42.1) |
| HDL cholesterol, mean (SD), mg/dL | 49.7 (14.2) | 49.9 (14.6) |
| eGFR, mL/min/1.73 m2, % | ||
| ≥90 | 1548 (29.0) | 1539 (28.9) |
| 60 to <90 | 2665 (50.0) | 2666 (49.9) |
| 45 to <60 | 768 (14.4) | 796 (14.9) |
| <45 | 353 (6.6) | 337 (6.3) |
| Clinical CVD, % | 1233 (23.1) | 1193 (22.4) |
| Statin use, % | 2781 (52.1) | 2872 (53.8) |
| Antihypertensive use medications, % | ||
| 0 | 534 (10.1) | 559 (10.9) |
| 1 | 1786 (33.5) | 1800 (33.7) |
| ≥2 | 3014 (56.5) | 2959 (55.4) |
| History of diabetesa | 2239 (42.0) | 2244 (42.0) |
| 10-year Framingham CVD risk %, median (IQR) | 22.7 (19.6) | 22.6 (19.4) |
| 10-year ASCVD risk %, median (IQR) | 22.3 (12.8) | 22.5 (13.0) |
SPRINT, Systolic Blood Pressure Intervention Trial; ACCORD-BP, Action to Control Cardiovascular Risk in Diabetes Blood Pressure; BMI, body mass index; SBP, systolic blood pressure; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease; SD, standard deviation; IQR, interquartile range; ASCVD, atherosclerotic cardiovascular disease.
History of diabetes was labelled as 0 for the SPRINT participants and 1 for the ACCORD-BP participants.
Baseline characteristics of participants in the trial (SPRINT or ACCORD-BP) according to the treatment assignment
| Variables . | Intensive treatment group (target SBP <120 mmHg; N = 5334) . | Standard treatment group (target SBP <140 mmHg; N = 5338) . |
|---|---|---|
| Age, mean (SD), year | 65.4 (8.3) | 65.6 (8.5) |
| Female, % | 2191 (41.1) | 2161 (40.5) |
| Race/ethnicity, % | ||
| Non-Hispanic White | 3165 (58.3) | 3102 (58.1) |
| Non-Hispanic Black | 1378 (25.8) | 1469 (27.5) |
| Hispanic | 489 (9.2) | 479 (9.0) |
| Other | 302 (5.7) | 288 (5.4) |
| Education status, % | ||
| Less than college | 3592 (67.3) | 3538 (66.3) |
| College or above | 1742 (32.7) | 1800 (33.7) |
| Uninsured, % | 673 (12.6) | 666 (12.5) |
| Living alone, % | 1317 (24.7) | 1382 (25.9) |
| Smoking, % | 676 (12.7) | 719 (13.5) |
| SBP, mean (SD), mmHg | 139.2 (15.8) | 139.5 (15.5) |
| BMI, mean (SD), kg/m2 | 31.1 (5.4) | 31.0 (5.2) |
| Total cholesterol, mean (SD), mg/dL | 191.8 (43.0) | 190.9 (42.1) |
| HDL cholesterol, mean (SD), mg/dL | 49.7 (14.2) | 49.9 (14.6) |
| eGFR, mL/min/1.73 m2, % | ||
| ≥90 | 1548 (29.0) | 1539 (28.9) |
| 60 to <90 | 2665 (50.0) | 2666 (49.9) |
| 45 to <60 | 768 (14.4) | 796 (14.9) |
| <45 | 353 (6.6) | 337 (6.3) |
| Clinical CVD, % | 1233 (23.1) | 1193 (22.4) |
| Statin use, % | 2781 (52.1) | 2872 (53.8) |
| Antihypertensive use medications, % | ||
| 0 | 534 (10.1) | 559 (10.9) |
| 1 | 1786 (33.5) | 1800 (33.7) |
| ≥2 | 3014 (56.5) | 2959 (55.4) |
| History of diabetesa | 2239 (42.0) | 2244 (42.0) |
| 10-year Framingham CVD risk %, median (IQR) | 22.7 (19.6) | 22.6 (19.4) |
| 10-year ASCVD risk %, median (IQR) | 22.3 (12.8) | 22.5 (13.0) |
| Variables . | Intensive treatment group (target SBP <120 mmHg; N = 5334) . | Standard treatment group (target SBP <140 mmHg; N = 5338) . |
|---|---|---|
| Age, mean (SD), year | 65.4 (8.3) | 65.6 (8.5) |
| Female, % | 2191 (41.1) | 2161 (40.5) |
| Race/ethnicity, % | ||
| Non-Hispanic White | 3165 (58.3) | 3102 (58.1) |
| Non-Hispanic Black | 1378 (25.8) | 1469 (27.5) |
| Hispanic | 489 (9.2) | 479 (9.0) |
| Other | 302 (5.7) | 288 (5.4) |
| Education status, % | ||
| Less than college | 3592 (67.3) | 3538 (66.3) |
| College or above | 1742 (32.7) | 1800 (33.7) |
| Uninsured, % | 673 (12.6) | 666 (12.5) |
| Living alone, % | 1317 (24.7) | 1382 (25.9) |
| Smoking, % | 676 (12.7) | 719 (13.5) |
| SBP, mean (SD), mmHg | 139.2 (15.8) | 139.5 (15.5) |
| BMI, mean (SD), kg/m2 | 31.1 (5.4) | 31.0 (5.2) |
| Total cholesterol, mean (SD), mg/dL | 191.8 (43.0) | 190.9 (42.1) |
| HDL cholesterol, mean (SD), mg/dL | 49.7 (14.2) | 49.9 (14.6) |
| eGFR, mL/min/1.73 m2, % | ||
| ≥90 | 1548 (29.0) | 1539 (28.9) |
| 60 to <90 | 2665 (50.0) | 2666 (49.9) |
| 45 to <60 | 768 (14.4) | 796 (14.9) |
| <45 | 353 (6.6) | 337 (6.3) |
| Clinical CVD, % | 1233 (23.1) | 1193 (22.4) |
| Statin use, % | 2781 (52.1) | 2872 (53.8) |
| Antihypertensive use medications, % | ||
| 0 | 534 (10.1) | 559 (10.9) |
| 1 | 1786 (33.5) | 1800 (33.7) |
| ≥2 | 3014 (56.5) | 2959 (55.4) |
| History of diabetesa | 2239 (42.0) | 2244 (42.0) |
| 10-year Framingham CVD risk %, median (IQR) | 22.7 (19.6) | 22.6 (19.4) |
| 10-year ASCVD risk %, median (IQR) | 22.3 (12.8) | 22.5 (13.0) |
SPRINT, Systolic Blood Pressure Intervention Trial; ACCORD-BP, Action to Control Cardiovascular Risk in Diabetes Blood Pressure; BMI, body mass index; SBP, systolic blood pressure; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease; SD, standard deviation; IQR, interquartile range; ASCVD, atherosclerotic cardiovascular disease.
History of diabetes was labelled as 0 for the SPRINT participants and 1 for the ACCORD-BP participants.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
